Latest stories

Evaluating management

E

The number one criteria which determines the performance of a company is the quality of the management. This is also the most difficult criteria to evaluate and one’s degree of success in evaluating the management determines the eventual success of the specific stock pick and long term returns of the portfolio.

If you are into trading, momentum investing or any other quantitative methods, then management or the nature of the business may not matter. However if like me, your approach to investing is to evaluate the long term economics and performance of a company and purchase the stock at a meaningful discount to the fair value, then management matters a lot.

Although it is easy to state the above point, it is not easy to execute it. There are no fixed formulae to evaluate management. A lot of times I have seen people either completely ignore the issue of management quality or get too focused on it. I will turn to the issue of too much focus later in the post.

I myself do not have any magic formulae to evaluate management. However I have a list of points (in my valuation template) against which I run a check on the company’s management. Let me discuss a few points below. These points are not exhaustive on their own, but may be a good place to start

Capital allocation record: This is the number one responsibility of the management. How does the management invest the free cash generated by the business? Is the management investing it in new opportunities at a high return (preferably more than 15%) or is the management chasing growth for growth’s sake?

A single year of good or bad performance may not be important. One should look at the track record for a number of years to evaluate the performance of the management on this count. A good way to do it is to look the incremental return on new investments. The formulae for calculating this number is simple – (net profit for current year – profit for five years back)/(Fixed asset + working capital for current year – same number five years back).
The above number should give you an idea of how well the management has invested in the last five or more years. A poor record means that the management is failing at its core responsibility.

Management compensation: A good management should be compensated well. However the compensation should be in line with the industry and within reasonable limits. I typically look for compensation to be between 3-5% of profits. Any more than that is a concern for me.

Shareholder communication: Does the management discuss the bad and good openly and with honesty. Do they crow about the good news and hide the bad news? Unfortunately in India shareholder communication is almost non-existent. Even companies doing well give a one page write up of the performance. Except for IT companies and a few others, shareholder communication is joke.

Accounting practice: Is the management conservative in accounting. Look for how the management is accounting for investments and hedge losses. Are they conservative in accounting for old debt (more than 6 months). Does the management have reasonable pension accounting?

Conflict of interest : related party transactions is the place to look for this point. I am on a watchout for any large transaction between affiliated companies (sister companies owned by management).

Past reputation: Has the management been reprimanded by SEBI or any other bodies? Do they have a past reputation of taking the investor for a ride?

I use the above list and more to evaluate the management. There is no formulae or wieghtage for any criteria and the eventual decision is bound to depend on past experience and a subjective assessment of all the factors. At the same time, if the management has a serious negative on any of the above points such as shoddy accounting or poor capital allocation record, I will just avoid the company and move on.

In the end ,there are a lot more companies to choose from and I would rather hold the cash than take grief from investing with a crooked management, not matter how good the numbers.

Over focus on the management
The other extreme I have seen is when investors fall completely in love with the company and follow each and every word and action of the management.

During the bull run of 2006-2007, I saw a lot of investors discuss and dissect every interview and utterance of the management on stock boards. I am all for tracking a company and reviewing the quarterly numbers and conference calls (if the management does that), however I find it silly to read every possible interview and press release and try to make sense out it.

I think companies which are over communicative and share every small scrap of information are focused too much on their media profile and may in some cases, be losing focus on the running their business. Investor who track every twist and turn of the company, risk missing the big picture as they convince themselves that they now understand the company much better as they have been following it very closely.

Getting fooled by management
Even if one is diligent in the analysis and evaluates the management from all aspects, it is possible to get fooled by the management – aka satyam.

So should one stop investing ? By that measure, one should not drive as you can have an accident.

My answer to reducing the risk is diversification. You do not put all your money into a single company. If one does a decent job of evaluating the management, the chances of getting cheated by a crooked management are reduced if not eliminated. The entire idea of investing is to manage risk with appropriate returns to compensate for it.

A quick note on the paid service
First, my apologies to all of you who have written to me. I have not responded to anyone.

I grossly underestimated the response. My initial plan was to respond to each email personally, but after a day or so I dropped it as the numbers went way above my estimates. A lot of you have expressed interest, but have also asked for the details of the service (rightly so !).

I am in the process of setting up an email service and would recommend anyone who is interested in the paid service to subscribe to it. I plan to use this email message service to discuss more details about the service and also share some exclusive content on it (the carrot for subscribing:)).

Some of you have raised the point on what will happen to this blog after I launch my service. Will it undergo a change? I have no plans to change the nature of the blog. It will always remain free and I will continue to share some of the ideas on the blog as before.

I however do not want to use this blog to broadcast about the service too much (though I will have occasional updates) as there are a lot of readers on the blog who would not be interested in it and I don’t want to spoil their experience with such posts.

As always, my thanks to all of you for reading and following my blog.

Stock analysis : FDC ltd

S

About
FDC is an Indian Pharmaceuticals company with an operating history of more than 50 years. The company is into formulations, synthetics, nutraceuticals and bio-tech with a focus on therapeutic groups of ORS, opthalmologicals, dermatologicals, Anti-biotics, Cardio and diabetes. The company has several well known brands such as electral, enerzal etc.

Financials
The company has maintained an ROE in excess of 20% for the last 10 years. In addition the company is conservatively financed with zero debt and excess cash position during the same period.

The company has maintained fixed asset turns (sales/ fixed asset) at the same levels by investing in fixed assets in line with the topline growth. The working capital turns (sales/ working capital) have improved from around 5 to 9+ levels in the last 10 years. This improvement has been driven mainly by an improvement in receivable turns (sales/ account receivables).

The net margins have improved from the 15% levels to 20% levels mainly due to drop in raw material prices.

Positives
The company has maintained a high ROE with a very conservative balance sheet. The company has maintained excess cash and financed growth with the free cash flow generated from operations.

The company has also been able to maintain a topline and bottom-line growth in excess of 15% in spite of high competition and change in the operating environment (changes in patent laws in 2005).The company announced a buy-back in 2008 and has been able to use the excess cash to reduce the number of outstanding shares.

The company has a consistent track record of introducing several new products every year and currently spends almost 3% of sales on R&D which is a crucial investment in the pharma business.
The company is conservative in other aspects of the business such as foreign acquisitions (none) or expanding in the foreign markets (exports are 10% of total turnover).

Risks
The company operates in a business characterized by a high level of competition from domestic and deep pocketed global pharma companies. Although company spends a substantial amount on R&D, global players such as JNJ spend in excess of 10% on R&D. As a result the R&D spend of the company is small by most standards and can be utilized only to develop the off patent molecules in the form of generics for the local and export market.

This is a very competitive business with low to moderate profitability and several other domestic pharma companies such as a CIPLA or Dr reddy’s have a major head start in the space (they are almost 10 times the size of FDC)

In addition the company is also into the consumer health space which is closer to FMCG than pharma products and requires a different set of skills and focus.

Competitive analysis
The industry is characterized by a large number of domestic and foreign competitors. India, China and other BRIC countries are the major growth areas now and all the major companies are now targeting India for growth. The market is already experiencing a high level of competition and activity. One indicator is the number of new product launches and corresponding marketing and sales cost.

The generics opportunity in the export markets of US, Europe and Japan is big with thin margins and high levels of competition.

In case of a drug coming off patent, the pricing typically drops off by more than 60% in the first year and by almost 80% by the third year of patent expiration. As a result these are high risk – high return, limited duration type of opportunities.

Management quality checklist

– Management compensation – Management compensation seems reasonable at less than 3% of net profit.
– Capital allocation record – Fairly good till date. The management has kept the ROE high, inspite of high cash levels. In addition the management has also used the excess capital to buy-back shares which is a sensible decision.
– Shareholder communication – Very sketchy. The mandatory disclosure in terms of the balance sheet, P&L and other schedules are as per the standards. However the company, like other mid cap companies, is very sketchy and does not provide enough discussion on the subjective parts of the business. It gives a very generic overview of the business and has not discussed the plans for the future in detail. If you compare with the annual reports of other pharma companies like Dr reddy’s, the differences are glaring. I can live without too much detail for a steel or a cement company as the numbers give a good picture, but for a pharma or IT company the subjective details are important to evaluate the future of the company. This is a big negative for me.
– Accounting practice – Seems ok. Nothing out of the ordinary
– Conflict of interest – Related party transactions seem fine. I could not find anything out of the ordinary.

Competitor analysis (top 2-3 competitors)
The main competitors for FDC are the domestic pharma companies such as Dr reddy’s, Cipla, Sun pharma and Ranbaxy. These companies are much larger than FDC and are not strictly comparable. At the same time, competition in the pharma industry is by segment. The term pharma is too broad for comparison. If one has to compare competitors, it would be by therapeutic groups such as anti-bioitics, cardio-vasculars, opthalmologicals etc.

FDC has a leading position in some segments such ORS and a few leading brands such as ZIPANT-D SR, 1-AL etc.

The net margins for FDC are comparable to the other top companies and the ROE is also in the same range of 20%+. The overall business risk to FDC is much lesser as the company has not expanded aggressively in the foreign markets. Conversely the returns and growth have been lower too compared to the other aggressive competitors such as Dr reddys, SUN pharma etc.

Valuation
A DCF calculation with a net margins of around 16-18% and 10-12% growth (both assumptions are conservative based on past history), gives a fair value of 120-140 per share. The company would be a good value below a price of 70 per share or if the company started doing far better than the assumptions in the above valuation.

Conclusion
FDC has been a conservatively managed company which has done fairly well in the past 10 years. The company has expanded mainly in the domestic markets and is now expanding slowly into exports via new ANDA filings. The company is likely to maintain a 10-15% growth in line with the market growth with some additional growth coming from exports.

As an investor, I would expect the company to give me moderate returns at low risk. I don’t think the company can be a multi-bagger in the short to medium term.

Disclosure : I have position in the stock. The above analysis is not to recommend the stock. So please do your own homework on it.

Quarterly result review – Some standouts

Q

The quarterly result for most companies are out and I have been reviewing the results of the companies in my portfolio. In most of the cases the results were as expected, but in some cases there have been some unexpected changes – in some cases good and a few not so good.

Cheviot Company – Now this is a company most of you would wonder, why the hell even invest in it? Cheviot is in the business of jute manufacturing and is located in West Bengal. I have written about company here and continue to hold a small position. This company operates in an unattractive industry in a business unfriendly state. The company workers go on a strike every alternate year and the compensation costs are now in excess of 15%.

If the above is not enough, the export market of the company has stagnated in the last few years due to the recession. So why hold this stock?

The company sells for less than cash on books, has been able to earn more than 15% on invested capital and pays out a fair dividend. The company is now focusing on the local market and has started growing again. However, all said and done, it is not the best of my picks although I have not lost money on it and I will exit in due course now.

Facor alloys – I wrote about this company recently here. The current quarter numbers are very good. If one excludes the one time power related charges, the company has earned almost 14 Crs in the quarter which is almost equal to the entire profit of the previous year.
This is a very cyclical business and one should not extrapolate the quarter numbers. However I think the company should do fine over a business cycle and is still selling cheap.

Lakshmi machine works – The company came out with decent numbers as expected. The key news on the company is that company has initiated a buyback which is good way of utilizing capital. I think the company could have done this earlier when the stock was cheaper, but it is quite likely that the management was conserving cash during the recession.

Gujarat gas – I have discussed the company here. The company came out with good topline and bottom line numbers(20% growth) The company continues to do well and is a well managed company. I personally think that once the company ties up more long term supply sources, it should be able to do even better and think that the fair value will keep increasing at a good rate.

The tech companies (Infosys, NIIT tech etc) – Infosys has come out with average numbers (10% sales growth, profit de-growth) in terms of growth. The company continues to generate a high return on capital, but the growth is now muted due varying factors such as recession in the US, exchange rates and rising costs in India. The valuations are still much higher and assume higher growth in the future. That may very well happen, though I am not betting my money on it – I have reduced my holding by a substantial amount already.

NIIT tech has had miserable performance in the last few years ( have written here about the company). The topline growth was non-existent and the silly foreign currency hedges kept biting the company. Those hedges are now being worked out and hopefully the management would not repeat the same mistake (of putting a multi-year currency hedge). The company has had a good topline and bottom line growth due to increased business in India (some of it is one time). I think the company should continue to give high single digit growth in the next few years.

The stock is not undervalued by a large margin and as a result I have reduced my position substantially.

The quarterly circus
Quarterly earnings are a big drama in the US. It is almost a ritual and every time a company misses its quarterly estimates, the stock gets punished severely. In India, the market was immune from this disease, that is till now. I have been noticing that in the last few quarters, any small slowdown or drop in growth is being punished severely and conversely, upside surprises are being rewarded.

A lot of participants may attribute this to higher efficiency and greater volumes etc. This may very well work for traders and in some cases for long time investors too. However I think it is bad for the companies and investors as a whole. A focus on quarterly numbers can cause management to take short sighted decisions which ends up destroying than creating value for the shareholders (remember Enron ?).

The focus of market on short term earnings may be or may be a good thing from varying points of view, but it is here to stay. In such a scenario, it can work for a long term shareholder if you can look past the temporary disappointment and buy the beaten up stock where the company will continue to do well in the future.

Truncated analysis: Shakti Met dor

T

About
Shakti Met Dor is a leading manufacturer of steel doors since 1995. The company was established primarily to manufacture steel doors, windows, and other building material products to cater to the construction industry. Shakti has expanded its facility to 180,000 Sq.ft of manufacturing and warehouse space capable of producing 300,000 doors and frames. Shakti has seven sales and marketing branches across the major metropolitan cities in India.

Financials
The company is in a niche business and has done fairly well in the last 8-10 years. The ROE has been maintained in excess of 20% with the recent drop due to new CAPEX and higher receivables. The Debt levels have gone up due to the new capacity and due to high additions to accounts receivables in the current year.

The inventory turns has remained at around 10 turns per year and the working capital turns in range of 3.5-4 which seems the reasonable. The total asset turns are at 2.3 which is likely to improve to around 3 with the capex being completed in the last one year.
The one key area of concern is the increase in accounts receivables which is now at around 150 days. I think this needs to be watched closely over the next few years.

Positives
The company operates in a profitable niche and has been able to scale up well in the last few years. The company has been able to deliver a topline growth in excess 20% in the last 10 years and bottom line growth (inspite of the recent drop) in roughly the same range.

The company has recently completed its capex cycle and with the growth in the construction, IT and other user industries, should be able to grow well. In addition the profit margins are likely to improve in the next few years, if the company is able to reduce the debt load and control the raw material costs. The improvement is not a given, but based on the past performance likely to happen.

Risks
There are several key risks in the business. The number one risk is the delisting plan of the company (see here). The management plans to delist the company and has offered around 195/ share. The management holds 56% of the company and needs 34% more to delist. Around 100 shareholders (including the promoters) hold around 90% of the company. I do not have details of these shareholders, but if the management has an informal agreement with them, then the delisting may happen at the proposed price. The minority shareholders holding 10% of the stock will not matter much in the reverse book building process.

A consent order was passed by SEBI on non-compliance of the company of the Substantial Acquisition of Shares and Takeovers Regulations in June 2010. It seems the promoters were acquiring the shares from the market since 1998 and have not disclosed it. This information is missing from the annual reports till 2008-2009. I think this does not inspire confidence

The other risk is the increase in the accounts receivables. This may not be as much as risk as the last quarter of 2010 has seen a sudden increase in topline and hence the year end numbers could be inflated due to that. However one has to watch this number closely as the debt more than 6 months doubled in 2009 and the total debt has increased further in 2010. This increases the risk of bad debt write-offs in the future.

Management quality checklist
– Management compensation: On the higher side. Management compensation is around 12% of net profit
– Capital allocation record: Has been sensible and good till date.
– Shareholder communication – Not good. The management has not been transparent in their communication (see the point on risks above)
– Accounting practice – Seems fine for most part with all the mandatory disclosures in the latest AR.
– Conflict of interest – None in the notes to account. However see the risks section for such incidents.
– Performance track record – Good from a business performance perspective. Corporate governance standards have not been satisfactory.

Conclusion
I started this analysis a few days back and was impressed with the fundamentals. On looking through the BSE filing, I noticed the delisting notice from the company and was thinking of this as an arbitrage or long term opportunity. However the nature of the shareholding (thanks to ninad for pointing that out), I have concerns on how the delisting will work out for the minority shareholder. In addition, some of the past actions do not inspire confidence.

As I discussed in the last post, my valuation template has a checklist which I go through before doing a more detailed analysis on the company. On running through the checklist, I have come across the risks mentioned earlier in this post. I am not too comfortable with those risks and hence inspite of good fundamentals have decided to drop this idea.

Note: If you hold the stock and don’t think the above issues are material enough, it may be so. However I am more conservative and don’t want to put my money on the line to test it out.

Subscription

Enter your email address if you would like to be notified when a new post is posted:

I agree to be emailed to confirm my subscription to this list

Recent Posts

Select category to filter posts

Archives